Results 51 to 60 of about 921,366 (160)

Myelination and Remyelination in Peripheral Nerve Injury: Mechanisms, Regulation, and Therapeutic Perspectives

MedComm, Volume 7, Issue 10, October 2026.
Peripheral nerve injury triggers axonal degeneration, myelin breakdown, and Schwann cell reprogramming. Remyelination requires reactivation of the SOX10–OCT6–KROX20/EGR2 transcriptional hierarchy, axonal NRG1–ErbB2/3 signaling, metabolic support, and coordinated immune regulation.
Li‐Xin Huang, Tao Sun, Yi‐Bo Zhao, Zhi‐Min Wu, Jun Sun, Ming‐Yang Li, Qing‐Yi Huo, Yun‐Mou Ou, Qing‐Tian Liang, Cong Ling, Bao‐Yu Zhang, Chuan Chen, Ying Guo, Hui Wang   +13 more
wiley   +1 more source

NKT Cell Responses to B Cell Lymphoma

Medical Sciences, 2014
Natural killer T (NKT) cells are a unique subset of CD1d-restricted T lymphocytes that express characteristics of both T cells and natural killer cells.
Junxin Li, Wenji Sun, Priyanka B. Subrahmanyam, Carly Page, Kenisha M. Younger, Irina V. Tiper, Matthew Frieman, Amy S. Kimball, Tonya J. Webb   +8 more
doaj   +1 more source

Untersuchung von Anti‐Glykan‐Antikörpern und Erforschung ihres medizinischen Potenzials mithilfe synthetischer Glykane

Angewandte Chemie, Volume 138, Issue 39, 21 September 2026.
Anti‐Glykan‐Antikörper spielen sowohl bei Gesundheit als auch bei Krankheit eine wesentliche Rolle. Der Zugang zu neuartigen Glykanstrukturen ermöglicht Fortschritte bei der Antikörpercharakterisierung für die Entdeckung von Biomarkern, die Antikörperentwicklung und das Impfstoffdesign.
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide [PDF]

, 2011
Activation of CD1d-restricted invariant NKT (iNKT) cells with the glycolipid α-galactosylceramide (α-GalCer) confers protection against disease in murine models, however, clinical trials in humans have had limited impact.
Hogan, Andrew E., Dunne, Margaret R., Xiangming Zhu, Exley, Mark A., Padraic G. Fallon, O'Reilly, Vincent P., Andrew E. Hogan, Sylvie Amu, Margaret R. Dunne, Zeng, Shijuan G., Dere, Ravindra T., Fallon, Padraic G., Zhu, Xiangming, Cashel O'Brien, Ravindra T. Dere, O'Brien, Cashel, Mark A. Exley, Derek G. Doherty, Cliona O'Farrelly, O'Farrelly, Cliona, Vincent O'Reilly, Doherty, Derek G., Shijuan G. Zeng, Amu, Sylvie   +23 more
core   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, Volume 65, Issue 39, 21 September 2026.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Programmable Antigen‐Specific Immunity via Self‐Adjuvanting Nanovaccines Co‐Delivering Immune Modulators

Angewandte Chemie, Volume 138, Issue 11, 9 March 2026.
The self‐adjuvanting vaccine—comprising a covalent conjugate of antigen and adjuvant—was formulated into cationic lipid nanoparticles smaller than 100 nm to facilitate uptake by immune cells, with supplemental adjuvants incorporated to modulate immune responses.
Keita Ito, Yoshiyuki Manabe, Shino Ohshima, Masatoshi Maeki, Manabu Tokeshi, Hiroshi Inaba, Kazunori Matsuura, Kazuya Kabayama, Yoshie Kametani, Koichi Fukase   +9 more
wiley   +2 more sources

Targeting the intratumoral microbiota to overcome cancer immunotherapy resistance

Interdisciplinary Medicine, Volume 4, Issue 5, September 2026.
This review delineates the mechanisms of intratumoral microbiota in cancer immunotherapy resistance, and offers strategies for microbiota‐targeted precision immunotherapy. Abstract Cancer remains a significant global health threat. The tumor microenvironment (TME) is a sophisticated ecological niche that exerts a pivotal effect on treatment outcomes ...
Bufu Tang, Tong Jiang, Yaling Lin, Wei Zhang, Hongjie Fan, Minjie Yang, Bingzhe Li, Yaozu Liu, Changyu Li, Xuran Jin, Wen Zhang, Zhiping Yan, Qianqian Zhao, Xuefeng Kan, Xudong Qu   +14 more
wiley   +1 more source

NKT TCR Recognition of CD1d-α-C-Galactosylceramide

, 2011
NKT cells respond to a variety of CD1d-restricted glycolipid Ags that are structurally related to the prototypic Ag α-galactosylceramide (α-GalCer). A modified analog of α-GalCer with a carbon-based glycosidic linkage (α-C-GalCer) has generated great ...
Patel, Onisha, Travis Beddoe, Robert Bittman, Steven A. Porcelli, McCluskey, James, Llebaria, Amadeu, Amadeu Llebaria, Castaño, A. Raúl, Hoe-Sup Byun, Godfrey, Dale I., Beddoe, Travis, Dale I. Godfrey, A. Raúl Castaño, Bittman, Robert, Richard W. Franck, Youssef Harrak, Harrak Serifi, Youssef, Zheng Liu, Jamie Rossjohn, Garth Cameron, Cameron, Garth, Byun, Hoe-Sup, Porcelli, Steven A., Rossjohn, Jamie, Onisha Patel, Daniel G. Pellicci, James McCluskey, Pellicci, Daniel G., Liu, Zheng, Franck, Richard W.   +29 more
core   +1 more source

Invariant Natural Killer T Cells Play a Role in Chemotaxis, Complement Activation and Mucus Production in a Mouse Model of Airway Hyperreactivity and Inflammation. [PDF]

PLoS ONE, 2015
CD1d-restricted invariant natural killer T (iNKT) cells play a critical role in the induction of airway hyperreactivity (AHR). After intranasal alpha-galactosylceramide (α-GalCer) administration, bronchoalveolar lavage fluid (BALF) proteins from mouse ...
Piia Karisola, Maili Lehto, Pia Kinaret, Niina Ahonen, Rita Haapakoski, Minna Anthoni, Masaru Taniguchi, Henrik Wolff, Anne Puustinen, Harri Alenius   +9 more
doaj   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, Volume 22, Issue 49, 1 September 2026.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source